PATH Stock Slides As Analysts Cut Price Targets

UiPath Inc. stocks have been trading down by -3.36 percent amid investor concerns over slowing automation demand and growth prospects.

Live Update At 16:48:35 EDT: On Thursday, September 24, 2026 UiPath Inc. stock [NYSE: PATH] is trending down by -3.36%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

UiPath (PATH) just reminded the market how fast sentiment can flip. The stock has slid from a late‑August close near $18.67 to about $12.60 by 2026/09/24. That is a steep drawdown for PATH in less than a month and tells traders this is now a broken near‑term trend, not a gentle pullback.

The daily chart shows the real damage started right after earnings. PATH fell from the mid‑$18s on 2026/09/03–04 to close near $15.19, then continued to bleed lower through mid‑September. The latest range, roughly $12.50–$13.00, shows a tired bounce and heavy supply overhead.

Intraday on 2026/09/24, PATH traded in a tight band around $12.60 with very small five‑minute candles. That kind of compressed action often reflects digestion after a big drop, not fresh accumulation. For short‑term trading, it means scalpers must size down and respect that momentum is weak.

More Breaking News

• WETO Stock Pulls Back As Traders Watch Key Levels
• BBD Stock Steadies As Banco Bradesco Draws Trader Focus
• PFSA Stock Jumps On Volatile Surge As Traders Circle
• UXIN Stock Rides Asian ADR Rally As Momentum Builds

Fundamentally, UiPath is not a disaster. PATH posted roughly $410.3M in quarterly revenue, with gross margin above 80% and an operating profit around $31.6M. The company generated positive free cash flow of about $29.3M and sits on more than $608.9M in cash with minimal debt. But at roughly 4.0x sales and a price/earnings near 19.8, the market now wants cleaner growth from PATH, not just solid margins.

Why Traders Are Watching PATH After The Selloff

PATH is back in focus because the stock didn’t just drift lower on some macro scare. UiPath cratered 11% in early trading after its latest quarterly release and ultimately finished down roughly 16%–17%. That kind of gap‑and‑flush move is exactly what momentum traders hunt, but only if they respect the risk.

The earnings themselves came in “mixed.” PATH put up strong gross margins and positive earnings, yet the Street judged the report and outlook as disappointing. The reaction tells you traders were leaning too bullish into the print, and when guidance and growth commentary failed to excite, the exits got crowded.

Analysts have since lined up to reset expectations. BofA raised its target on PATH from $13 to $15, but kept an Underperform rating and openly questioned whether AI will truly accelerate annual recurring revenue. UBS cut its target from $19 to $15, while Truist moved from $17 to $14. RBC lowered its PATH target from $17 to $15 and labeled UiPath a “show‑me” story until results back up the automation and AI pitch.

There is also a macro headwind. RBC highlighted that application‑focused software names like UiPath, Asana, and Intuit are lagging as AI spending shifts toward cyber, infrastructure, and data platforms. For PATH, that means it is fighting both company‑specific doubts and a sector rotation away from its lane. For traders, that combo often leads to choppy bounces, sharp short‑covering pops, and then more fade.

Conclusion

For active traders, PATH now sits in that tricky zone between panic and patience. The stock is heavily off its recent highs, analysts have collectively chopped price targets to the $14–$16 band, and the Street consensus sits at Hold. That tells you sentiment is cautious but not in total capitulation. There is room for rallies, but each spike in UiPath will run into trapped longs from the $16–$18 area.

At the same time, UiPath’s balance sheet and margins give PATH real staying power. The company is generating positive cash flow, posting 82.6% gross margins, and running with very low leverage. Those numbers limit bankruptcy‑style tail risk and keep longer‑term funds engaged, which can anchor PATH once the selling pressure cools.

UiPath still has to prove that its AI‑driven automation story translates into faster, cleaner ARR growth. Until that shows up in the numbers, many on the Street will treat PATH as a “show‑me” trade, not a must‑own AI leader. That mindset tends to cap the upside of each bounce.

For the Sykes‑style community, the playbook is clear: let PATH show its hand on the chart, focus on clean multi‑day patterns, and honor risk first. As Tim Sykes often says, “The market rewards prepared traders, not hopeful ones.” And as Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” That perspective reinforces the idea that PATH is a ticker to study patiently, waiting for high‑probability trading setups rather than forcing trades. This coverage of UiPath and PATH is for educational and research purposes only, meant to help traders study the volatility, not to tell anyone what to buy or sell.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.